一种新型「饲料内」递送平台用于口服DNA疫苗接种抗IPNV,在大西洋鲑中实现高保护
研究开发了脂质体DNA疫苗的「饲料内」口服递送平台,疫苗构建体编码VP2衣壳蛋白免疫原区。用IPNV攻毒比较免疫与未免疫的降海前大西洋鲑死亡率,单剂1mgpDNA/kg鱼·d的相对存活率(RPS)为58.2%,双剂2mgpDNA/kg鱼·d为66%。疫苗诱导可检测的VP2特异性抗体,对鱼安全,未在池水中检出pDNA,但粪便和未食用饲料沉积物中有疫苗残留。
要点
- 口服脂质体DNA疫苗编码VP2免疫原区,单剂RPS 58.2%、双剂66%。
- 疫苗诱导可检测的VP2特异性抗体,并显示对鱼安全。
- 池水未检出pDNA,但粪便和未食用饲料沉积物中检出疫苗残留。
核心结论
- 饲料内脂质体DNA疫苗接种平台在大西洋鲑抗IPNV中成功验证,口服疫苗具有免疫原性且对鱼安全,口服后提供显著保护。
研究设计与样本
- 研究描述脂质体DNA疫苗「饲料内」口服免疫制剂的开发与体内评估,并通过IPNV攻毒比较免疫与未免疫降海前大西洋鲑的死亡率。
主要发现
- 口服疫苗诱导可检测水平的VP2特异性抗体。
- IPNV攻毒后,单剂1mgpDNA/kg鱼·d的相对存活率(RPS)为58.2%,双剂2mgpDNA/kg鱼·d为66%。
- 疫苗对鱼安全,池水中未检出pDNA,但粪便和未食用饲料沉积物(固体废物)中存在疫苗残留。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DNA vaccination has emerged as a promising tool against infectious diseases of farmed fish. Oral delivery allows stress-free administration that is ideal for mass immunization and of paramount importance for infectious pancreatic necrosis (IPN) and other viral disease that affect young salmonids and cause economic losses in aquaculture worldwide. METHODS: We describe the development and in vivo assessment of an "in-feed" formulation strategy for oral immunization with liposomal DNA vaccines, by delivering a vaccine construct coding for an immunogenic region of the VP2 capsid protein. A challenge against IPNV was carried out to determine the vaccine efficacy, by comparing the mortality of pre-smolt Atlantic salmons immunized and non-immunized with the oral vaccine. The antibody response (ELISA) and hematological parameters after immunization were examined, as well as the vaccine effect on the growth and internal structures of fry salmons (histological analysis). The vaccine distribution in the experimental tank after oral administration was investigated by HPLC and PCR amplification. RESULTS: The oral vaccine induced detectable levels of VP2-specific antibodies and conferred significant protection following IPNV challenge, with relative percent survivals (RPS) of 58.2%, for single dose (1mgpDNA/kgfish⋅d), and 66% for double dose (2mgpDNA/kgfish⋅d). We further provide evidence in favour of the vaccine safety to fish and demonstrated absence of pDNA in the tank water, but presence of vaccine residues in faeces and unconsumed feed sediments (solid wastes). CONCLUSION: The delivery platform for liposomal DNA vaccination via feed was successfully proved against IPNV in Atlantic salmon, showing the oral vaccine to be immunogenic and safe for fish, and providing significant protection after oral administration. The "in-feed" technology for oral DNA vaccination holds potential to be applied against IPNV and other pathogens that currently threaten the aquaculture worldwide.
引用
- Reyes M, Ramírez C, Ñancucheo I, et al. A novel "in-feed" delivery platform applied for oral DNA vaccination against IPNV enables high protection in Atlantic salmon (Salmon salar). Vaccine. 2016. PMID: 28012776. doi:10.1016/j.vaccine.2016.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。